Skip to content

A Study to Test the AdaptDx Pro Agreement in Rod Intercept Time With the AdaptDx in Healthy Subjects With Normal Vision (FlashBack)

A Prospective, Single-Center Study to Test the AdaptDx Pro Agreement in Rod Intercept Time With the AdaptDx in Healthy Subjects With Normal Vision (FlashBack)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07803588
Acronym
FlashBack
Enrollment
24
Registered
2026-09-03
Start date
2026-09-15
Completion date
2027-03-01
Last updated
2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adult Participants

Keywords

Dark adaptation, rod-mediated dark adaptation

Brief summary

The purpose of this study is to test the AdaptDx Pro agreement in Rod Intercept (RI) time with the AdaptDx tabletop (AdaptDx) in healthy subjects with normal vision.

Interventions

DIAGNOSTIC_TESTAdaptDx Tabletop vs AdaptDx Pro

Two variations of AdaptDx dark adaptation devices.

Sponsors

AdaptDx, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
22 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

Subjects enrolled in the study will be required to meet all the following criteria for both eyes: 1. Male or female between the ages of 22 and 49 (inclusive) at Visit 1 2. ETDRS BCVA letter score of 85 (Snellen equivalent of 20/20) or better at Visit 1 3. Able to communicate well with the Investigator and able to understand and comply with the requirements of the study 4. Informed of the nature of this study and has provided written informed consent in accordance with institutional, local and national regulatory guidelines

Exclusion criteria

1. Unable to follow simple instructions, operate a response button or maintain attention for 20 minutes 2. Diagnosis or history of any ocular disease or disorder 3. Serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgement of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study 4. Presence of or history of malignancy within the past year of Visit 1 other than non-melanoma skin or squamous cell cancer or cervical carcinoma in-situ 5. Is non-ambulatory 6. History of drug, alcohol or substance abuse within 3 months prior to Visit 1 7. Has received an investigational drug or treatment with an investigational device within 3 months prior to Visit 1 8. In the opinion of the Investigator, is unlikely to comply with the study protocol

Design outcomes

Primary

MeasureTime frameDescription
Rod Intercept TimeImmediately after the dark adaptation testthe time in minutes it takes for the eye's rod photoreceptors to recover sensitivity after a bright flash of light

Countries

United States

Contacts

CONTACTCindy Croissant VP, Clinical Operations, BS, MBA
ccroissant@opzira.com858 397 1021

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 4, 2026